Skip to main content

Market Overview

Preventative Wellness Startup Reperio Health Nets $6 Million in Seed Funding to Expand Proactive Health Monitoring

Share:

Portland, Oregon-based venture will offer home wellness kits containing sensors for testing health metrics, empowering people to monitor and track their health over time

Reperio Health™, the only at-home health assessment and biometric screening system that provides comprehensive results immediately, is poised to take health engagement and patient empowerment to the next level. The company today announced its seed capital raise of $6 million, supporting plans to accelerate growth and expand proactive health monitoring to the employer market.

"Nearly 9 out of 10 large employers currently offer some sort of workplace wellness program, which equates to roughly 63 million people in the U.S. alone," said Travis Rush, Reperio Health co-founder and CEO. "Unfortunately, the typical process for health screenings is time-consuming and inconvenient, so many people procrastinate and put these off for years. Reperio is making it easy by bringing health screenings right to peoples' door."

Reperio's patent-pending at-home health assessment enables employees and private individuals to perform a broad range of screenings at their convenience while in the comfort of their own home. The FDA-approved sensors in the Reperio kit include a blood test to measure levels of total cholesterol, HDL, LDL, triglycerides and glucose, in addition to tests for blood pressure, resting heart rate, Body Mass Index (BMI) and Relative Fat Mass (RFM).

Reperio's HIPAA-compliant mobile app begins with a wellness screening to understand lifestyle patterns. Then, the biometric screening walks customers through the testing process using voiceovers, animations and videos to make the process as user-friendly as possible. Once they complete the full screening, the Reperio app provides them real-time results with context that explains their results in a consumer-friendly and easy to understand format.

Rush added, "Employers understand the opportunity in helping employees proactively manage their health. It's been the catalyst for companies investing in a multitude of workplace wellness programs in recent years. We've seen the shift over the last decade to a higher adoption of virtual care and telehealth and realized that we could give people easier access to their data and ultimately, more control over their own health."

In addition to their initial launch into the employer market, Reperio's at-home health assessments will be made available to health plans, retirement facilities, fitness and nutrition practitioners and directly to individuals who are personally motivated to better understand and control their health data.

Reperio's oversubscribed seed round was co-led by Caduceus Capital Partners in Nashville, Tenn., and Rogue Venture Partners in Portland, Ore., with additional investment from Liquid 2 Ventures and G Ventures, both out of the San Francisco Bay Area.

Reperio Health is based in Portland, Ore. Rush is the former CEO of Sightbox, who sold to Johnson & Johnson in 2017. He is joined at Reperio Health by co-founder and Chief Technology Officer Matt Wallington, also of Sightbox. For more information, visit www.reperiohealth.com.

About Reperio Health

Reperio is the only at-home health assessment that provides comprehensive results immediately. Our patent-pending at-home health assessment enables employees and private individuals to perform biometric screenings at their convenience while in the comfort of their own home. For more information, visit www.reperiohealth.com.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com